1. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, FTD/TPI, with Ramucirumab Murine Version DC101 in a Mouse Syngeneic Cancer Transplantation Model
   Kenta Tsunekuni et al, 2020, Journal of Clinical Medicine CrossRef
2. Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs
   Jadd Shelton et al, 2016, Chemical Reviews CrossRef
3. Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study
   Pilar García-Alfonso et al, 2021, Cancers CrossRef
4. Two Cases of Long-Term Control of Metastatic Colorectal Cancer via FTD/TPI plus Bevacizumab in Elderly Patients
   Masatsune Shibutani et al, 2018, Case Reports in Oncology CrossRef
5. TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
   Cheng-Jiang Liu et al, 2021, Gastroenterology Research and Practice CrossRef
6. Targeting thymidine phosphorylase alleviates resistance to dendritic cell immunotherapy in colorectal cancer and promotes antitumor immunity
   Ankush Paladhi et al, 2022, Frontiers in Immunology CrossRef
7. Redefining Later-Line Therapy in Metastatic Colorectal Cancer
   Karen Yee, 2017, European Medical Journal CrossRef
8. Comparison of the efficacy and safety of third-line treatments for metastatic colorectal cancer: a systematic review and network meta-analysis
   Loulu Gao et al, 2023, Frontiers in Oncology CrossRef
9. Further Therapeutic Options in Heavily Pretreated Colorectal Cancer Patients
   Aneta L. Zygulska, 2019, Multidisciplinary Approach for Colorectal Cancer CrossRef
10. Biomarkers of Trifluridine-Tipiracil Efficacy
    Ioannis A. Voutsadakis, 2021, Journal of Clinical Medicine CrossRef